ISRG robotic-assisted surgery leadership

What happened: Intuitive Surgical (ISRG) reported strong Q1 2023 results, with sales and adjusted EPS up 23% and 38% respectively. Total procedures grew 17%, while instrument and accessory sales jumped 23%. The company's bottom line totaled $821.5 million, or $2.28 per share, up from $698.4 million, or $1.92 per share, in Q1 2022. ISRG's da Vinci robotic platform has performed over 20 million procedures. Meanwhile, ISRG faces increased competition in the robotic surgery sector.

Market impact: ISRG's robust performance has driven investor confidence, with notable fund managers like Israel Englander loading up on the stock. The company's leadership in robotic-assisted surgery has pushed its shares higher, making it a top pick among pure-play robotics stocks. However, ISRG's near-term prospects are clouded by trade war-related challenges, which have caused its shares to lag broader equities.

What to watch next: ISRG is set to report Q2 2023 earnings on July 25, 2023, which will provide further insight into its growth trajectory. Additionally, investors should keep an eye on the resolution of the U.S.-China trade war, as it could significantly impact ISRG's near-term performance. Lastly, the company's continued innovation and international expansion will be crucial to maintaining its market leadership.